Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2022

View Archived Issues

FKBP51 blockade ameliorates cognitive function during obesity

New antibacterials described by the Centre National de la Recherche Scientifique (CNRS)

Bayer discovers soluble guanylate cyclase activators

Cancer Research Technology presents new ALDH1A3 inhibitors

LG Chem identifies new proteasome inhibitors

Scripps Research Institute, Vova Ida Therapeutics patent compounds for treating neurodegeneration

CM-1758 shows cytotoxic effects in models of bladder cancer

PXL-065 demonstrates efficacy in preclinical models of ALD

PP2A inhibition sensitizes cancer cells and inhibits their growth

Biomea's menin inhibitor BMF-219 shows prolonged glycemic control in two rat models of diabetes

Noggin expression has prognostic value in pancreatic cancer

First female-specific Alzheimer's risk gene found

Anti-MASP-2 antibody TST-004 shows promise for MASP-2-dependent diseases in vitro and in vivo

Polysaccharide-protein antigen pneumococcal vaccine effective in type 3 invasive disease model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...